Categories
Connect with us on LinkedIn
Waiver of Consent vs Waiver of Written Consent
One is very common, the other is rarely granted. Learn the key differences between waiver of consent &...
Unlocking FDA’s Vision for PRO Collection in RWE: Timing, Methods, and Insights
Discover FDA's guidance on collecting PROs for Real-World Evidence (RWE), focusing on timing, methods, and improving data quality.
Understanding Phase 4 Clinical Trials: A Critical Component of Post-Marketing Insight to Drugs in the Real-World
When it comes to Phase 4 clinical trials, Castor's cutting-edge Real-World Evidence (RWE) platform is your key to...
5 Key Takeaways from the FDA’s Real-World Evidence Guidance
A deep dive into the evolving regulatory environment, the innovative approaches emerging in RWE, and the critical importance...
Navigating the Evolving Regulatory and Data Landscape
A deep dive into the evolving regulatory environment, the innovative approaches emerging in RWE, and the critical importance...
Do We Still Need Patients in Tomorrow’s Trials? Modeling Placebo Effect and Beyond
Discover the transformative role of AI in clinical trials, with expert insights from Derk Arts and MaryAnne Rizk...
eCOA: Afterthought or Essential Strategy? An Expert’s View on Choosing and Developing an eCOA Strategy
The Evolving Landscape of eCOA in Clinical Trials Clinical trials have long grappled with the complexities of data...
Evaluating “Bother” as a Component of Patient-Reported Outcomes in Clinical Studies
Patient-reported outcome (PRO) instruments refer to multiple scales and questionnaires designed to collect patients’ personal feedback on their...
Under pressure: what it takes to validate a cuffless blood pressure device
When a company brings a cuffless, continuous blood pressure monitor to market, the wristband is the easy part....
5 Best Practices for Getting Started with ePRO
Electronic Patient Reported Outcomes (ePRO) can become a powerhouse for gathering high-quality data directly from patients. To help...
Can BYOD help us end an era of waste and burden in eCOA?
Bring Your Own Device (BYOD) represents the future of eCOA, and prioritizes flexibility & convenience for trial participants....
Measuring the true patient experience in Cancer Trials with eCOA / ePRO
Shedding light on the complexities and advancements in measuring PROs, drug tolerability, and quality of life in cancer...
The Place of COAs / PROs in the Future of Healthcare
Learn how integrating Patient-Reported Outcomes (PROs) into clinical trials can drive success in Value-Based Care (VBC).
Accelerating AI Innovation in Pharma: Collaboration versus Competition
Should clinical trial companies collaborate to speed up innovation in AI, or is a healthy dose of competition...
10 FAQs on eConsent
To gain a deeper understanding of eConsent, we have gathered the 10 most frequently asked questions that address...
Don’t Overengineer It: Hybrid Designs Overcome Barriers in DTx Clinical Trials
At DTxEast 2023, Castor joined a panel discussion to answer big questions when designing DTx clinical trials
A Digital-First Mindset Shift on eConsent
eConsent plays a pivotal role in optimizing modern clinical trials, but the nuance around its adoption for pharmaceutical...
Preparing Your eConsent Study for IRB Approval
In this blog we cover how eConsent benefits trials and aligns with IRB ethical commitments, how to prepare...
Connect with us on LinkedIn
